Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 20.05 is 14% above its 2-year average of 17.63, around the middle of its 2-year range (0.00–35.33).
As of the fiscal period ended Tuesday, June 30, 2026. 19.31% below its 12-month average of 24.84.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 20.05.
QUICK RATIO (ACID-TEST)
20.05
QUICK RATIO (ACID-TEST) AVG TTM
24.84
QUICK RATIO (ACID-TEST) AVG 3Y
N/A
QUICK RATIO (ACID-TEST) AVG 5Y
N/A
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
-19.31%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.35
median of 870 covered companies
CURRENT VS SECTOR MEDIAN
+497.48%
vs the sector median at left
Sionna Therapeutics, Inc.
Market Cap
$214.46M
Quick Ratio (Acid-Test)
20.05
TTM Avg
24.84
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$214.24M
Quick Ratio (Acid-Test)
5.13
TTM Avg
3.45
3Y Avg
2.59
5Y Avg
2.27
Market Cap
$215.07M
Quick Ratio (Acid-Test)
344.31
TTM Avg
177.51
3Y Avg
95.13
5Y Avg
76.52
Market Cap
$216.91M
Quick Ratio (Acid-Test)
4.07
TTM Avg
3.65
3Y Avg
6.88
5Y Avg
10.38
Market Cap
$210.98M
Quick Ratio (Acid-Test)
5.36
TTM Avg
6.17
3Y Avg
11.50
5Y Avg
11.99
Market Cap
$218.30M
Quick Ratio (Acid-Test)
21.96
TTM Avg
18.45
3Y Avg
17.11
5Y Avg
21.15
Market Cap
$210.41M
Quick Ratio (Acid-Test)
10.89
TTM Avg
11.84
3Y Avg
8.89
5Y Avg
15.32
Market Cap
$209.91M
Quick Ratio (Acid-Test)
5.72
TTM Avg
5.91
3Y Avg
5.85
5Y Avg
7.15
Market Cap
$208.31M
Quick Ratio (Acid-Test)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sionna Therapeutics, Inc. (SION) | $214.46M | 20.05 | 24.84 | N/A | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $214.24M | 5.13 | 3.45 | 2.59 | 2.27 |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $215.07M | 344.31 | 177.51 | 95.13 | 76.52 |
| Prelude Therapeutics Incorporated (PRLD)vs › | $216.91M | 4.07 | 3.65 | 6.88 | 10.38 |
| Lyell Immunopharma, Inc. (LYEL)vs › | $210.98M | 5.36 | 6.17 | 11.50 | 11.99 |
| Keros Therapeutics, Inc. (KROS)vs › | $218.30M | 21.96 | 18.45 | 17.11 | 21.15 |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.41M | 10.89 | 11.84 | 8.89 | 15.32 |
| Compugen Ltd. (CGEN)vs › | $209.91M | 5.72 | 5.91 | 5.85 | 7.15 |
| Electra Therapeutics Inc. (ETRA)vs › | $208.31M | N/A | N/A | N/A | N/A |
| Profound Medical Corp. (PROF)vs › | $220.93M | 5.31 | 10.41 | 9.80 | 12.54 |
Quick Ratio
20.05
Excludes inventory
Current Ratio
20.05
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 20.05 |
| 2026-03-31 | 22.60 |
| 2025-12-31 | 20.61 |
| 2025-09-30 | 25.61 |
| 2025-06-30 | 35.33 |
| 2025-03-31 | 28.73 |
| 2024-12-31 | 14.49 |
| 2024-09-30 | 21.66 |
| 2024-06-30 | 0.00 |
| 2024-03-31 | 0.00 |
| 2023-12-31 | 4.88 |
